The Hormone Scare of 2002 — Were We Right to Panic about our Hearts?
Part 2 of 4 in our series: Menopause Hormone Therapy and Your Heart Missed Part 1? Start here: "Hormones and Your Heart: Why Doctors Keep Changing Their Minds."
The year 2002 changed everything.
Women threw their hormone prescriptions in the trash. Doctors stopped writing them. A therapy that had been standard practice for decades became, almost overnight, something nobody wanted to touch. And the reason all of this happened? A massive clinical trial called the Women's Health Initiative (WHI) — the largest study of its kind ever conducted — was abruptly shut down.
But here's the question worth asking twenty years later: were we right to panic?
Before the WHI: The HERS Study Sent the First Warning Shot
Before we get to the WHI, there was an important earlier study that already had the medical community uneasy.
The HERS trial — the Heart and Estrogen/Progestin Replacement Study — was the first major randomized controlled trial to test hormone therapy on heart health directly. The women enrolled weren't the average menopause patient though. These were women who already had established coronary heart disease — prior heart attacks, coronary procedures, or confirmed arterial blockages. Half received a combination hormone therapy (conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA)), and half received a placebo.
The results were a genuine shock.
Not only did hormone therapy fail to protect these women, it also doubled their risk of a cardiac event in the very first year. Nobody saw that coming.
What HERS uncovered is now called the "early hazard phenomenon." Hormone therapy has what's called a prothrombotic effect — it can increase clotting factors and trigger inflammation. In women who already have arterial plaque — those built-up deposits lining blood vessel walls — that extra clotting activity can destabilize those plaques and cause them to rupture. That's what triggers a heart attack.
The lesson from HERS was important and clear: if you already have heart disease, hormone therapy is not only unhelpful — it may actively put you at risk.
Then Came the WHI — and the Whole World Heard About It
If HERS was a warning, the WHI was a five-alarm fire.
The Women's Health Initiative enrolled over 27,000 women — healthy women, not those with pre-existing heart disease — and was designed to finally give us definitive answers on hormone therapy. But the trial was stopped early when data showed women in the hormone group had higher rates of:
Pulmonary embolism (blood clots in the lungs)
Stroke
Invasive breast cancer
Heart attack-not statistically significant
Coronary heart disease-not statistically significant
The headlines were immediate and alarming. And the fallout was swift — women stopped their prescriptions, doctors stopped offering them, and the conversation about hormone therapy went largely silent for years.
So — Were We Right to Panic?
Partly yes. Partly no.
The HERS findings were solid and important: hormone therapy genuinely carries risk for women who already have cardiovascular disease, and that lesson still stands today.
But the WHI? That story turned out to be far more complicated than the headlines suggested — and the most important nuances were buried in data that most people never saw.
Key Takeaway from Part 2
The HERS study gave us a critical warning: hormone therapy can be harmful for women who already have heart disease. The WHI amplified that fear on a massive scale. Both studies were important — but the full picture was far from complete.
Next up — Part 3: "The Fine Print Nobody Read in the Big Hormone Study." It turns out the WHI had a significant flaw in interpretation that changed everything — and when researchers went back to look more carefully at the data, a very different story began to emerge.
